Interesting....?
http://www.thelatestnews.com/single-...pes-of-cancer/
Peer reviewed article: http://www.cell.com/cancer-cell/abst...108(15)00349-9
Printable View
Interesting....?
http://www.thelatestnews.com/single-...pes-of-cancer/
Peer reviewed article: http://www.cell.com/cancer-cell/abst...108(15)00349-9
Yes, interesting. There is a lot of research going on out there which may, or may not, at some point in the future become a product that has the potential to displace existing products.
But until then: It is nearly Movember.
Best Wishes
Paper Tiger
FWIW, I'm not over-worried by the Urological Assn's assessment of CxB, given its negativity about biomarker technology overall. From my understanding, Kaiser Permanente has a reputation for making its own assessments notwithstanding whatever pressure may be exerted by the "industry" in its various forms including Big Pharma. It has the resources to do this and as the biggest health operator in the US with thousands of highly qualified staff is not scared to make independent decisions.
Kaiser and the AUA work together on alot of projects--I haven't seen any evidence of pressure.However if there is,it would be interesting to see this--Could you please show us?
Nothing specific re the AUA, Skid, just general reading along the lines that KP encourages staff to be open to medical ideas that not regarded as conventional industry-wide and offering them to patients as an option. That's not to suggest they ignore standard practice, but KP is run by its own medical staff who have significant autonomy on a regional basis.
While all this discussion is relevant on general share trading, most of what is discussed doesn't apply to PEB. It is a startup... therefore has no 5 year relevant earnings history (they give lots of the tests away ). KWs theories work well with established companies with real trading history. In contrast, PEB is a bottomless hole currently that is trying to lure both shareholders and customers in. Hopefully the overlap of overzealous nz investors trying to make a product with some merit fly with the big pharma will last until the overseas medical insurance fraternity et al. decide to give it a big tick for use. OR not.
Personally I'm a startup risk lover so peb ticked my box initially although the $ spent into it have moved past a low risk startup and into a lightweight returning performer area, however; the returns aren't there and the time delay required until profitability is dragging on, meaning my $ are probably better pulled out at a loss and dropped quickly into a mine or product that has already started production and are in the start of their growth phase rather than testing continuously. Ditto NTL ...GAFMO (my newly coined sharetrading mnemonic)
The bottom line though is whether this process gains enough credibility to be paid for by Medicare or insurance providers--This report has just chipped away at those odds a bit more--but anything can happen. Two things must happen--a glowing report by Kaiser--and the adoption of the test in big numbers (which most likely means it gets covered financially by insurance etc.)
It could ,however achieve enough sales to carry on as a going concern,but not on the level that was hoped for. Wouldnt be great for the SP but would still provide a service.The upcoming numbers will provide a guide as to how they are doing on that front.
Strictly from a patient point of view,that blood test sounds very encouraging and could have the potential to save many lives
Disc. Im under no illusions that big pharma is able to apply pressure and even manipulate things into their favor ranging from lobbying the Gov. to out rite deciet,but normally this dirt shows up on tests sponsored by the companies themselves but we cant rule anything out including Kaiser which is not without controversy once in a while. (I dont think so in this case,but they are a business,and they,like all large businesses, have to listen to their accountants)
Meanwhile,unless the numbers show they are doing fine on their own,most off their eggs are in one basket (kaiser)
https://nzx.com/files/attachments/223999.pdf
1H16 lab throughput up just 19% on 2H15.